Compile Data Set for Download or QSAR
Report error Found 33 Enz. Inhib. hit(s) with all data for entry = 11579
TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628474(US20230339856, Compound (IId))
Affinity DataIC50: 150nMAssay Description:The rhGAA enzyme sold under the name Myozyme used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628473(US20230339856, Compound (IIc))
Affinity DataIC50: 220nMAssay Description:The rhGAA enzyme sold under the name Myozyme used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM50583379(CHEMBL5028138 | US20230339856, Compound (IIb))
Affinity DataIC50: 390nMAssay Description:The rhGAA enzyme sold under the name Myozyme used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM18351((2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-tr...)
Affinity DataIC50: 410nMAssay Description:The rhGAA enzyme sold under the name Myozyme used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM50583378(CHEMBL5028084 | US20230339856, Compound (IIa))
Affinity DataIC50: 420nMAssay Description:The rhGAA enzyme sold under the name Myozyme used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM50124581(CHEMBL3621529 | US20230339856, Compound (IIg))
Affinity DataIC50: 460nMAssay Description:The rhGAA enzyme sold under the name Myozyme used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628475(US20230339856, Compound (IIf))
Affinity DataIC50: 870nMAssay Description:The rhGAA enzyme sold under the name Myozyme used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM18355(N-Butyl-DNJ | (2R,3R,4R,5S)-1-butyl-2-(hydroxymeth...)
Affinity DataKi:  3.10E+3nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM18351((2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-tr...)
Affinity DataKi:  3.40E+3nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM50583381(CHEMBL5029066 | US20230339856, Compound (IIb1))
Affinity DataKi:  6.40E+3nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628473(US20230339856, Compound (IIc))
Affinity DataKi:  7.60E+3nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628478(US20230339856, Compound (IIh))
Affinity DataIC50: 9.70E+3nMAssay Description:The rhGAA enzyme sold under the name Myozyme used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM50583383(CHEMBL5028005 | US20230339856, Compound (IIb3))
Affinity DataKi:  1.08E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628480(US20230339856, Compound (IIk))
Affinity DataIC50: 1.16E+4nMAssay Description:The rhGAA enzyme sold under the name Myozyme used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628488(US20230339856, Compound (IIc1))
Affinity DataKi:  1.30E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM50583379(CHEMBL5028138 | US20230339856, Compound (IIb))
Affinity DataKi:  1.30E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628479(US20230339856, Compound (IIj))
Affinity DataIC50: 1.52E+4nMAssay Description:The rhGAA enzyme sold under the name Myozyme used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628474(US20230339856, Compound (IId))
Affinity DataKi:  1.89E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628489(US20230339856, Compound (IIr))
Affinity DataKi:  2.00E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628482(US20230339856, Compound (IIn))
Affinity DataIC50: 2.46E+4nMAssay Description:The rhGAA enzyme sold under the name Myozyme used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628489(US20230339856, Compound (IIr))
Affinity DataIC50: 2.95E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM50583383(CHEMBL5028005 | US20230339856, Compound (IIb3))
Affinity DataIC50: 2.96E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628486(US20230339856, Compound (IIb7))
Affinity DataIC50: 3.16E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628488(US20230339856, Compound (IIc1))
Affinity DataIC50: 3.29E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628473(US20230339856, Compound (IIc))
Affinity DataIC50: 3.72E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628485(US20230339856, Compound (IIx1))
Affinity DataIC50: 4.03E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628481(US20230339856, Compound (IIm))
Affinity DataIC50: 4.50E+4nMAssay Description:The rhGAA enzyme sold under the name Myozyme used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM50583381(CHEMBL5029066 | US20230339856, Compound (IIb1))
Affinity DataIC50: 4.91E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM50583379(CHEMBL5028138 | US20230339856, Compound (IIb))
Affinity DataIC50: 1.04E+5nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628474(US20230339856, Compound (IId))
Affinity DataIC50: 1.82E+5nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM628475(US20230339856, Compound (IIf))
Affinity DataIC50: 2.97E+5nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM50583378(CHEMBL5028084 | US20230339856, Compound (IIa))
Affinity DataIC50: 3.41E+5nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetLysosomal alpha-glucosidase(Human)
UniversitÉ

US Patent
LigandPNGBDBM50124581(CHEMBL3621529 | US20230339856, Compound (IIg))
Affinity DataIC50: 3.87E+5nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent